G6PD Deficiency: Exploring the Relationship with Different Medical Disorders
DOI:
https://doi.org/10.22317/jcms.v9i5.1433Keywords:
G6PD Deficiency, Oxidative Stress, Reactive Oxygen Species, Medical DisordersAbstract
G6PD deficiency (G6PDD) is associated with oxidative stress resulting from an imbalance between reactive oxygen species (ROS) production and the body's ability to counteract. In this review, we explore the adverse effects of G6PDD on diverse physiological processes and disease outcomes. Past studies have demonstrated the association between G6PDD and various other diseases, indicating a link between G6PDD to heightened oxidative stress by accelerating virus replication, worsening infection severity, and weakening the body's defense mechanisms. Such stress is critical in the destruction of red blood cells (RBCs) during infections and has a detrimental impact on redox signaling, ultimately impacting cell health and promoting cancer development. Furthermore, it impairs endothelial function by lowering the nitric oxide (NO) level and increasing stress, resulting in detrimental cardiac consequences and reduced myocardial antioxidant capacity. Because ROS contributes to inflammation, this imbalance causes conditions such as early atherosclerosis. It also compromises the functionality of NO-regulated bronchodilators and conditions such as G6PDD exacerbate the risks of kidney damage. Elevated ROS levels can also induce harm in retinal tissues, blood vessels, brain cells, and Beta-cells, hence quickening the progression of diseases like Diabetic Retinopathy. Furthermore, oxidative stress plays a significant role in cerebral ischemic pathogenesis, contributing to neurodegenerative disorders. Additionally, decreased NADPH level is vital for NO synthesis as it can impact blood vessel relaxation and can potentially lead to ischaemic priapism. Investigating the association between G6PDD and other medical conditions is crucial as it helps to identify possible approaches to mitigate oxidative stress, thereby preventing associated complications and diseases, particularly in situations where current treatment options are insufficient.
References
Geck RC, Powell NR, Dunham MJ. Functional interpretation, cataloging, and analysis of 1,341 glucose-6-phosphate dehydrogenase variants. American Journal of Human Genetics [Internet]. 2023;110(2):228–39. Available from: https://doi.org/10.1016/j.ajhg.2023.01.003
Wei X, Kixmoeller K, Baltrusaitis E, Yang X, Marmorstein R. Allosteric role of a structural NADP+ molecule in glucose-6-phosphate dehydrogenase activity. Proceedings of the National Academy of Sciences of the United States of America. 2022;119(29):1–8.
Sadhewa A, Seyoum SC, Acharya S, Devine A, Price RN, Mwaura M, et al. A Review of the Current Status of G6PD Deficiency Testing to Guide Radical Cure Treatment for Vivax Malaria. 2023;
Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Radical Biology and Medicine. 1995;19(4):523–8.
Nicolas MG, Javier LM, Litan RRR, Gonzaga A, Punzalan JM. Association of Sex and Zinc Deficiency with Glucose-6-Phosphate Dehydrogenase Deficiency in Filipino Children. Philippine Journal of Science. 2022;151(1):13–23.
Alakbaree M, Amran S, Shamsir M, Ahmed H, Hamza M, Alonazi M, et al. Construction of A Complete Human Glucose-6-Phosphate Dehydrogenase Dimer Structure Bound to Glucose-6-Phosphate and Nicotinamide Adenine Dinucleotide Phosphate Cofactors Using Molecular Docking Approach. 2022;
Parsanathan R, Jain SK. Glucose-6-phosphate dehydrogenase (G6PD) deficiency is linked with cardiovascular disease. Hypertension Research [Internet]. 2020;43(6):582–4. Available from: http://dx.doi.org/10.1038/s41440-020-0402-8
Alakbaree M, Amran S, Shamsir M, Ahmed HH, Hamza M, Alonazi M, et al. Human G6PD variant structural studies: Elucidating the molecular basis of human G6PD deficiency. Gene Reports. 2022;101634.
Alakbaree M, Hashim A, Ahmed HH, Hasan F, Al-hili A, Shahir M, et al. A computational study of structural analysis of Class I human glucose-6-phosphate dehydrogenase ( G6PD ) variants : Elaborating the correlation to chronic non-spherocytic hemolytic anemia ( CNSHA ). Computational Biology and Chemistry [Internet]. 2023;104(April):107873. Available from: https://doi.org/10.1016/j.compbiolchem.2023.107873
Zahed Pasha Y, Zamani V, Zahed Pasha E, Zamani M. Glucose-6-phosphate dehydrogenase enzyme deficiency in Iranian newborns: A systematic review and meta-analysis. Caspian Journal of Pediatrics [Internet]. 2020 [cited 2020 Apr 9];6(1):376–86. Available from: http://caspianjp.ir/article-1-105-en.html
Rani S, Malik FP, Anwar J, Paracha RZ. Investigating effect of mutation on structure and function of G6PD enzyme : a comparative molecular dynamics simulation study. 2022;
Songtanin B, Molehin AJ, Brittan K, Manatsathit W. Hepatitis E virus infections. 2023;(June).
Teymoori-rad M, Marashi SM. Vitamin D and Covid-19 : From potential therapeutic effects to unanswered questions. 2020;(August):1–16.
Araujo T, Katiyar V, Zamora JAG. Acute retroviral syndrome presenting with hemolytic anemia induced by G6PD deficiency. Tropical Medicine and Infectious Disease. 2019;4(1):4–7.
Jain SK, Parsanathan R, Levine SN, Bocchini JA, Holick MF, Vanchiere JA. The potential link between inherited G6PD deficiency, oxidative stress, and vitamin D deficiency and the racial inequities in mortality associated with COVID-19. Free Radical Biology and Medicine [Internet]. 2020;161(October):84–91. Available from: https://doi.org/10.1016/j.freeradbiomed.2020.10.002
Bhutra A, Giri PP, Ganguly N. Acute hepatic failure with hemolytic anemia due to Hepatitis A infection with coexistent glucose-6-phosphate dehydrogenase deficiency. Pediatric Infectious Disease [Internet]. 2015;7(2):50–2. Available from: http://dx.doi.org/10.1016/j.pid.2015.04.002
Miri-Aliabad G, Khajeh A, Shahraki T. Prevalence of G6PD deficiency in children with hepatitis A. International Journal of Hematology-Oncology and Stem Cell Research. 2017;11(2):92–5.
Sharma D, Singh O, Juneja D, Goel A, Garg SK, Shekhar S. Hepatitis A virus-induced severe hemolysis complicated by severe glucose-6-phosphate dehydrogenase deficiency. Indian Journal of Critical Care Medicine: Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine. 2018;22(9):670.
Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA. Hepatitis E virus: Infection beyond the liver? Journal of Hepatology [Internet]. 2017;66(5):1082–95. Available from: http://dx.doi.org/10.1016/j.jhep.2016.11.016
Yang HC, Ma TH, Tjong WY, Stern A, Chiu DTY. G6PD deficiency, redox homeostasis, and viral infections: implications for SARS-CoV-2 (COVID-19). Free Radical Research [Internet]. 2020;0(0):1–11. Available from: https://doi.org/10.1080/10715762.2020.1866757
Au TY, Wiśniewski OW, Benjamin S, Kubicki T, Dytfeld D, Gil L. G6PD deficiency—does it alter the course of COVID-19 infections? Annals of Hematology [Internet]. 2023;102(7):1629–36. Available from: https://doi.org/10.1007/s00277-023-05164-y
Song J, Sun H, Zhang S. The Multiple Roles of Glucose-6-Phosphate Dehydrogenase in Tumorigenesis and Cancer Chemoresistance. 2022;
Ryan K, Tekwani BL. Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency. Pharmacology and Therapeutics [Internet]. 2021;222:107788. Available from: https://doi.org/10.1016/j.pharmthera.2020.107788
Sanna M, Caocci G, Ledda A, Orrù F, Fozza C, Deias P, et al. Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia. Leukemia and Lymphoma [Internet]. 2017;58(11):2558–64. Available from: http://dx.doi.org/10.1080/10428194.2017.1312666
Matsumura S, D’Addiaro C, Slivano OJ, De Miguel C, Stier C, Gupte R, et al. Mediterranean G6PD variant rats are protected from Angiotensin II-induced hypertension and kidney damage, but not from inflammation and arterial stiffness. Vascular Pharmacology [Internet]. 2022;145(December 2021):107002. Available from: https://doi.org/10.1016/j.vph.2022.107002
Dominguez A, Muppidi V, Gupta S. Hyperaldosteronism. 2018;
Dore MP, Parodi G, Portoghese M, Pes GM. The Controversial Role of Glucose-6-Phosphate Dehydrogenase Deficiency on Cardiovascular Disease: A Narrative Review. Oxidative Medicine and Cellular Longevity. 2021;2021.
Hecker PA, Leopold JA, Gupte SA, Recchia FA, Stanley WC. Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease. American Journal of Physiology - Heart and Circulatory Physiology. 2013;304(4).
Park J, Choe SS, Choi AH, Kim KH, Yoon MJ, Suganami T, et al. Increase in glucose-6-phosphate dehydrogenase in adipocytes stimulates oxidative stress and inflammatory signals. Diabetes. 2006;55(11):2939–49.
Park J, Chung JJ, Kim JB. New evaluations of redox regulating system in adipose tissue of obesity. Diabetes research and clinical practice. 2007;77(3):S11–6.
Park J, Rho HK, Kim KH, Choe SS, Lee YS, Kim JB. Overexpression of glucose-6-phosphate dehydrogenase is associated with lipid dysregulation and insulin resistance in obesity. Molecular and Cellular Biology. 2005;25(12):5146–57.
Pretsch W, Charles DJ, Merkle S. X-linked glucose-6-phosphate dehydrogenase deficiency in Mus musculus. Biochemical genetics. 1988;26(1–2):89–103.
Himes BE, Koziol-White C, Johnson M, Nikolos C, Jester W, Klanderman B, et al. Vitamin D modulates expression of the airway smooth muscle transcriptome in fatal asthma. PLoS ONE. 2015;10(7):1–26.
Fois A, Dore MP, Manca A, Scano V, Pirina P, Pes GM. Association between glucose‐6‐phosphate dehydrogenase deficiency and asthma. Journal of Clinical Medicine. 2021;10(23).
Prado CM, Martins MA, Tibério IFLC. Nitric oxide in asthma physiopathology. International Scholarly Research Notices. 2011;2011.
Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nature Reviews Disease Primers [Internet]. 2021;7(1). Available from: http://dx.doi.org/10.1038/s41572-021-00284-z
Hakeem GLA, Naeem EAA, Swelam SH, Fotoh LEMA, Mazary AAM El, Fadil AMA, et al. Detection of occult acute kidney injury in glucose-6-phosphate dehydrogenase deficiency anemia. Mediterranean Journal of Hematology and Infectious Diseases. 2016;8(1):1–7.
Kang Q, Yang C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biology [Internet]. 2020;37:101799. Available from: https://doi.org/10.1016/j.redox.2020.101799
Adinortey MB, Owusu RK, Galyuon IKA, Ekloh W, Owusu I, Larbi DA. G-6-PD deficiency - a potential risk factor for development of diabetes mellitus. 2011;2(August):1017–21.
Niazi GA. Glucose-6-phosphate dehydrogenase deficiency and diabetes mellitus. International journal of hematology. 1991;54(4):295–8.
Santana MS, Monteiro WM, Costa MRF, Sampaio VS, Brito MAM, Lacerda MVG, et al. High frequency of diabetes and impaired fasting glucose in patients with glucose-6-phosphate dehydrogenase deficiency in the Western brazilian Amazon. The American journal of tropical medicine and hygiene. 2014;91(1):74.
Karadsheh NS, Quttaineh NA, Karadsheh SN, El-Khateeb M. Effect of combined G6PD deficiency and diabetes on protein oxidation and lipid peroxidation. BMC Endocrine Disorders. 2021;21(1):4–8.
Khan AU, Mohany M, Khan HU, Fozia F, Khan S, Kamran N, et al. Anti - Alzheimer , antioxidants , glucose - 6 - phosphate dehydrogenase e ff ects of Taverniera glabra mediated ZnO and Fe 2 O 3 nanoparticles in alloxan - induced diabetic rats. 2023;1–12.
Beli E, Yan Y, Moldovan L, Vieira CP, Gao R, Duan Y, et al. Restructuring of the gut microbiome by intermittent fasting prevents retinopathy and prolongs survival in db/db mice. Diabetes. 2018;67(9):1867–79.
Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nature Reviews Neurology. 2023;19(1):19–38.
Evlice A, Ulusu NN. Glucose-6-phosphate dehydrogenase a novel hope on a blood-based diagnosis of Alzheimer’s disease. Acta Neurologica Belgica. 2017;117(1):229–34.
Martins RN, Harper CG, Stokes GB, Masters CL. Increased Cerebral Glucose‐6‐Phosphate Dehydrogenase Activity in Alzheimer’s Disease May Reflect Oxidative Stress. Journal of Neurochemistry. 1986;46(4):1042–5.
Morrison BF, Thompson EB, Shah SD, Wharfe GH. Ischaemic priapism and glucose-6-phosphate dehydrogenase deficiency: A mechanism of increased oxidative stress? West Indian Medical Journal. 2014;63(6):658–60.
Finley DS. Glucose-6-phosphate dehydrogenase deficiency associated stuttering priapism: Report of a case. Journal of Sexual Medicine. 2008;5(12):2963–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Journal of Contemporary Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
